{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:50:00Z","timestamp":1780879800268,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.ijantimicag.2010.11.032","type":"journal-article","created":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T09:11:16Z","timestamp":1297069876000},"page":"283-290","source":"Crossref","is-referenced-by-count":15,"title":["Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections"],"prefix":"10.1016","volume":"37","author":[{"given":"Petros I.","family":"Rafailidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/17460913.4.1.13","article-title":"Prulifloxacin: clinical studies of a broad-spectrum quinolone agent","volume":"4","author":"Giannarini","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0010","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200464190-00005","article-title":"Prulifloxacin","volume":"64","author":"Keam","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.4.1.27","article-title":"Prulifloxacin: a new antibacterial fluoroquinolone","volume":"4","author":"Prats","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0020","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent","volume":"26","author":"Tougou","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0025","first-page":"201","article-title":"Pharmacokinetics and tolerability of prulifloxacin after single oral administration","volume":"53","author":"Picollo","year":"2003","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2010.11.032_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pupt.2005.09.009","article-title":"Pharmacologic characteristics of prulifloxacin","volume":"19","author":"Matera","year":"2006","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1128\/AAC.01260-08","article-title":"Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea","volume":"53","author":"Fritsche","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10096-002-0709-1","article-title":"In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones","volume":"21","author":"Prats","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0045","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.45.12.3616-3622.2001","article-title":"In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates","volume":"45","author":"Montanari","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijantimicag.2005.07.015","article-title":"Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa","volume":"26","author":"Roveta","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0055","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijantimicag.2007.01.009","article-title":"In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance","volume":"29","author":"Gualco","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0060","first-page":"24","article-title":"In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens [in Italian]","volume":"14","author":"Noviello","year":"2006","journal-title":"Infez Med"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10156-004-0352-0","article-title":"In vitro activity of \u03b2-lactams and quinolones against AmpC \u03b2-lactamase-producing Escherichia coli","volume":"11","author":"Yamasaki","year":"2005","journal-title":"J Infect Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2010.11.032_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003495-199500492-00087","article-title":"NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients","volume":"49","author":"Mikamo","year":"1995","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2010.11.032_bib0075","first-page":"50","article-title":"The in vitro activity of NM441, a new quinolone, against anaerobic bacteria","volume":"44","author":"Kato","year":"1996","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0080","first-page":"27","article-title":"Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis","volume":"2","author":"Blasi","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2010.11.032_bib0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pupt.2005.09.007","article-title":"Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis","volume":"19","author":"Cazzola","year":"2006","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1753465808094914","article-title":"Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers","volume":"2","author":"Pasqua","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000063623","article-title":"Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis","volume":"69","author":"Grassi","year":"2002","journal-title":"Respiration"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00192-006-0233-4","article-title":"Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure","volume":"18","author":"Ghezzi","year":"2007","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1179\/joc.2009.21.5.535","article-title":"14-day prulifloxacin treatment of acute uncomplicated cystitis in women with recurrent urinary tract infections: a prospective, open-label, pilot trial with 6-month follow-up","volume":"21","author":"Cai","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000084432","article-title":"Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections","volume":"74","author":"Carmignani","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4081\/uij.2003.69","article-title":"Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women","volume":"17","author":"Cervigni","year":"2003","journal-title":"Urogynaecologia"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0120","first-page":"73","article-title":"Antibacterial prophylaxis in endourological procedures [in Italian]","volume":"58","author":"Prezioso","year":"2006","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0125","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1179\/joc.2007.19.3.304","article-title":"Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial","volume":"19","author":"Giannarini","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1358\/mf.2010.32.1.1423885","article-title":"Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study","volume":"32","author":"Cai","year":"2010","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijantimicag.2008.11.012","article-title":"Serenoa repens associated with Urtica dioica (ProstaMEV\u00ae) and curcumin and quercitin (FlogMEV\u00ae) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study","volume":"33","author":"Cai","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0140","first-page":"1","article-title":"Single dose versus 5-day course of oral prulifloxacin in antimicrobial prophylaxis for transrectal prostate biopsy [in Italian]","volume":"59","author":"Mari","year":"2007","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0145","first-page":"1","article-title":"Antibiotic prophylaxis with prulifloxacin in women undergoing induced abortion: a randomized controlled trial [in Italian]","volume":"60","author":"Caruso","year":"2008","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0150","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th Infectious Diseases Society of America (IDSA) Annual Meeting","article-title":"A randomized, double-blind, placebo controlled phase III trial of prulifloxacin as therapy for traveler's diarrhea","author":"DuPont","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0155","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Prulifloxacin, a new fluoroquinolone treatment for traveler's diarrhea","author":"Steffen","year":"2009"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette\u2013Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0165","first-page":"195","article-title":"The diabetic infected foot: outpatients management and experience with prulifloxacin","volume":"7","author":"Cavani","year":"2007","journal-title":"Trends Med"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11908-001-0091-7","article-title":"The new age of prostatitis","volume":"3","author":"Lloyd","year":"2001","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2005.04.013","article-title":"The role of antibiotics in chronic bacterial prostatitis","volume":"26","author":"Wagenlehner","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/0044011-200929010-00003","article-title":"Penetration of orally administered prulifloxacin into human prostate tissue","volume":"29","author":"Giberti","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0185","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.juro.2007.11.081","article-title":"Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis","volume":"179","author":"Nickel","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0190","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0090-4295(03)00565-X","article-title":"Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study","volume":"62","author":"Bundrick","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijantimicag.2003.07.006","article-title":"Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils","volume":"23","author":"Reato","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00345-003-0335-2","article-title":"The role of cytokines in prostatitis","volume":"21","author":"Jang","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jac\/46.2.241","article-title":"Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin","volume":"46","author":"Tullio","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.40.3.739","article-title":"Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes","volume":"40","author":"Ozaki","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0215","first-page":"791","article-title":"In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin and gatifloxacin [in Japanese]","volume":"55","author":"Shimizu","year":"2002","journal-title":"Jpn J Antibiot"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2010.11.032_bib0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003495-199958002-00021","article-title":"Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis","volume":"58","author":"Weidner","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0225","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijantimicag.2008.03.014","article-title":"Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis","volume":"32","author":"Naber","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00126839-200708060-00005","article-title":"Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations","volume":"8","author":"Gorlero","year":"2007","journal-title":"Drugs R D"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0235","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1179\/joc.2009.21.6.646","article-title":"The impact of prulifloxacin on vaginal Lactobacillus microflora: an in vivo study","volume":"21","author":"Tempera","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00192-009-0931-9","article-title":"Methicillin-resistant Staphylococcus aureus sepsis after elective vaginal prolapse surgery","volume":"21","author":"Marzolf","year":"2010","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7547\/1000052","article-title":"Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics","volume":"100","author":"Nicolau","year":"2010","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0250","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/AAC.48.3.1012-1016.2004","article-title":"In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections","volume":"48","author":"Edmiston","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2010.11.032_bib0255","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1086\/504487","article-title":"Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"43","author":"Rice","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2010.11.032_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The role of PK\/PD parameters to avoid selection and increase of resistance: mutant prevention concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0270","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","article-title":"Arrhythmias associated with fluoroquinolone therapy","volume":"29","author":"Falagas","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/11319400-000000000-00000","article-title":"Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study","volume":"30","author":"Rosignoli","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2131\/jts.29.63","article-title":"Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia","volume":"29","author":"Akita","year":"2004","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0285","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(03)02180-0","article-title":"Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk","volume":"477","author":"Lacroix","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11319780-000000000-00000","article-title":"Does the prulifloxacin ECG study prove cardiac safety of the drug?","volume":"30","author":"Malik","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2010.11.032_bib0295","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.clpt.6100010","article-title":"Cardiac repolarization and the safety of new drugs defined by electrocardiography","volume":"81","author":"Morganroth","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910005583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910005583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T11:28:21Z","timestamp":1559993301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910005583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0924857910005583"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.11.032","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}